News

Proteapex Therapeutics in the News

July 24, 2019

Dr. Marina D’Angelo, CSO, will pitch ECPF-2, the novel therapeutic to treat periodontal disease, to Fortune 500 companies and investors. The pitch was coordinated through the National Council of Entrepreneurial Tech Transfer (NCET2).

April 23, 2018

ProteaPex Therapeutics is presenting several posters at the 2018 Experimental Biology meeting in San Diego, CA. In addition, we are featured in a short film as part of the Thought Leadership Series.

See the film here

March 9, 2018

ProteaPex Therapeutics won First Place on March 9 in the Orthopedic Research Society's First Annual Business Plan Competition in New Orleans, Louisianna. They detailed the business plan for their lead therapeutic, Pexagen, an injectable osteoarthritis treatment for companion animals.

February 26, 2018

ProteaPex Therapeutics has been chosen as a top 5 finalist in the Orthopedic Research Society's Business Innovation Competition. CSO, Marina D'Angelo, will pitch to an expert panel of judges on March 9 in New Orleans.

February 26, 2018

ProteaPex Therapeutics will be the subject of a short documentary in the Thought Leadership Film Series produced by WebsEdge. The documentary will air on EBTV during the Experimental Biology Conference in San Diego this April 2018.

February 13, 2018

ProteaPex Therapeutics was awarded their third patent, COMPOSITIONS AND METHODS FOR INHIBITION OF MMP8:MMP8-SUBSTRATE INTERACTIONS for their novel therapeutic ECPF-2.

April 22, 2017

Two scientific posters detailing our ECPF therapeutics will be presented this week at the Experimental Biology meeting in Chicago, Illinois (April 22-26, 2017).

November 14, 2016

Our periodontal disease therapeutic, ECPF-2, is the subject of a proof-of-concept competition grant proposal to the University City Science Center. The winners will be announced early 2017.

See the video here

April 2, 2016

Three scientific posters detailing our ECPF therapeutics will be presented this week at the Experimental Biology meeting in San Diego, California (April 2-6, 2016). One of the ECPF1 presentations is a finalist for the American Association of Anatomists Undergraduate Student Poster Award.

July 24, 2019

Dr. Marina D’Angelo, CSO, will pitch ECPF-2, the novel therapeutic to treat periodontal disease, to Fortune 500 companies and investors. The pitch was coordinated through the National Council of Entrepreneurial Tech Transfer (NCET2).

October 30, 2015

ProteaPex Therapeutics has been invited to participate in this year's Life Science Futures Partnerships in Sciences Symposium to be held in Philadelphia,PA.

http://lifesciencesfuture.com/symposium-partnerships-in-science/

Marina D'Angelo, CSO, will present osteoarthritis animal model data of efficacy for ECPF-1 as a therapeutic and human tooth model data of efficacy of ECPF-2 as a therapeutic in stabilizing dental restoration bonding.

October 13, 2015

SECOND PATENT GRANTED TO PROTEAPEX THERAPEUTICS

ProteaPex Therapeutics has been granted its second patent on the"Compositions and Methods for Inhibition of MMP:MMP-Substrate Interactions" by the US Patent Office.

ProteaPex Therapeutics has developed an innovative disease modifying therapeutic technology with applications in the treatment of post-traumatic osteoarthritis and durability of dental restorations. The family of peptide inhibitors, Extracellular Matrix Protection FactorsT (ECPF) represent a broad base of products for treatment of orthopedic, dental and wound healing health issues.

September 3, 2015

Marina D'Angelo, PhD, CSO and co-founder of ProteaPex Therapeutics, was the recent subject of a Faculty Spotlight.

See the video here

May 8, 2015

Our lead OA product, ECPF-1, was recently featured on public radio in a segment on pet osteoarthritis. You can listen to it here: https://www.insidehighered.com/audio/2015/05/04/canine-osteoarthritis

Listen here

March 31, 2015

ProteaPex Therapeutics participated in a platform presentation at the Experimental Biology meeting in Boston, MA entitled "Development of a Serum-free, Three Dimensional Cell Culture Model for Primary Human Articular Chondrocytes to Test Potential Therapeutics".

News from 2013

PATENT GRANTED TO PROTEAPEX THERAPEUTICS

December 16, 2013
ProteaPex Therapeutics has been granted a patent on the "Compositions and Methods for Inhibition of MMP13:MMP-Substrate Interactions” by the US Patent Office.
ProteaPex Therapeutics has developed an innovative disease modifying therapeutic technology to treat post-traumatic osteoarthritis PTOA, Extracellular Matrix Protection Factor™ (ECPF-1). This is a novel, safe and effective intra-articular injection that reduces the pain and damage caused by OA by targeting individual protein pairs.
In addition, using ECPF-1, ProteaPex Therapeutics is developing a broad base of products for treatment of orthopedic, periodontal and wound healing health issues.


Jeff Boily, ProteaPex's Chairman will be part of the Selection Committee panel at the 2013 Animal Health Investment Forum. The KC Animal Health Investment Forum provides a unique opportunity for venture capital funds, investment firms and animal health companies to hear from emerging companies with the newest technology.

NEWS FROM 2012

ProteaPex Therapeutics (as ChondroPro Biosciences) won the People's Choice Award in the 2012 Wharton Business Plan Competition. More...



ProteaPex Therapeutics Presents New Designs for Fracture Non-Union Therapeutics in San Diego, CA at the American Society of Bone and Mineral Research Annual Meeting